Skip to main content

Table 3 Immunocytochemistry analysis related to HPV-DNA in 110 cervical samples

From: Immunocytochemical study of TOP2A and Ki-67 in cervical smears from women under routine gynecological care

Human papillomavirus N Ki-67+ TOP2A+ Ki-67+/TOP2A+ ICC+ (%)
N (%) p OR (95 % IC) N (%) p OR (95 % IC) N (%) p OR (95 % IC) N (%) p OR (95 % IC)
HPV+ 83 45 (54.2) 0.0003 6.809 (2.16–21.43) 45 (54.2) 0.0142 3.383 (1.29–8.86) 36 (43.4) 0.0004 9.574 (2.12–43.11) 54 (65.1) 0.0065 3.724 (1.48–9.33)
 With cytological abnormalities 28 26 (92.8) 0.0001 24.63 (5.26–115.2) 20 (71.4) 0.0357 3.00 (1.12–7.96) 19 (67.8) 0.0021 4.791 (1.77–12.55) 27 (96.4) 0.0001 28.00 (3.55–220.8)
 W/o cytological abnormalities 55 19 (34.4)    25 (45.4)    17 (30.9)    27 (49.1)   
HPV 27 4 (14.8)    7 (25.9)    2 (7.4)    9 (33.3)   
 With cytological abnormalities 4 0 (−) 0.4286 3 (75) 1.00 0 (−) 1.00 3 (75) 1.00
 W/o cytological abnormalities 23 2 (8.7)    3 (13.0)    1 (4.3)    4 (17.4)